Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 9Gynecologic 5Gastrointestinal 5Thoracic 4Other solid neoplasm 2Head & Neck 2Genitourinary 2Dermatologic 2Sarcoma 1NET 1Endocrine 1

Conditions

Thyroid Neoplasms 1Nasopharyngeal Carcinoma 1

Interventions

Cisplatin 315Radiotherapy 139Cetuximab 133pembrolizumab 131Docetaxel 122Carboplatin 119Radiotherapy, Intensity-Modulated 97Fluorouracil 94Paclitaxel 92Nivolumab 64Gemcitabine 50toripalimab 46Radiation 44Drug Therapy 39Capecitabine 39Magnetic Resonance Spectroscopy 38Surgical Procedures, Operative 33camrelizumab 31130-nm albumin-bound paclitaxel 29apatinib 27tislelizumab 26Chemoradiotherapy 26Specimen Handling 25Bevacizumab 24durvalumab 23Albumin-Bound Paclitaxel 23nimotuzumab 22lenvatinib 21Sorafenib 21Platinum 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × famitinib × Head & Neck × Clear all
NCT06146985 2023-11-28

Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer

Ruijin Hospital

Phase 2 Unknown
67 enrolled
Head & Neck

Thyroid Neoplasms

NCT01392235 2019-01-22

Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
58 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡